198 related articles for article (PubMed ID: 25738301)
21. IFITM proteins inhibit HIV-1 protein synthesis.
Lee WJ; Fu RM; Liang C; Sloan RD
Sci Rep; 2018 Sep; 8(1):14551. PubMed ID: 30266929
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
[TBL] [Abstract][Full Text] [Related]
23. IFITM proteins restrict viral membrane hemifusion.
Li K; Markosyan RM; Zheng YM; Golfetto O; Bungart B; Li M; Ding S; He Y; Liang C; Lee JC; Gratton E; Cohen FS; Liu SL
PLoS Pathog; 2013 Jan; 9(1):e1003124. PubMed ID: 23358889
[TBL] [Abstract][Full Text] [Related]
24. IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity.
Gómez-Herranz M; Taylor J; Sloan RD
J Biol Chem; 2023 Jan; 299(1):102741. PubMed ID: 36435199
[TBL] [Abstract][Full Text] [Related]
25. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
26. Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity.
Jia Q; Jiang X; Yu F; Qiu J; Kang X; Cai L; Li L; Shi W; Liu S; Jiang S; Liu K
Bioorg Med Chem Lett; 2012 Apr; 22(7):2393-5. PubMed ID: 22406118
[TBL] [Abstract][Full Text] [Related]
27. Analysis of IFITM-IFITM Interactions by a Flow Cytometry-Based FRET Assay.
Winkler M; Wrensch F; Bosch P; Knoth M; Schindler M; Gärtner S; Pöhlmann S
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31398796
[TBL] [Abstract][Full Text] [Related]
28. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
[TBL] [Abstract][Full Text] [Related]
29. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.
Gómara MJ; Sánchez-Merino V; Paús A; Merino-Mansilla A; Gatell JM; Yuste E; Haro I
Biochim Biophys Acta; 2016 Jun; 1860(6):1139-48. PubMed ID: 26905802
[TBL] [Abstract][Full Text] [Related]
30. Aurothiolates inhibit HIV-1 infectivity by gold(I) ligand exchange with a component of the virion surface.
Okada T; Patterson BK; Ye SQ; Gurney ME
Virology; 1993 Feb; 192(2):631-42. PubMed ID: 8421903
[TBL] [Abstract][Full Text] [Related]
31. Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins.
Wrensch F; Hoffmann M; Gärtner S; Nehlmeier I; Winkler M; Pöhlmann S
J Virol; 2017 Jan; 91(2):. PubMed ID: 27807233
[TBL] [Abstract][Full Text] [Related]
32. Antiviral Role of IFITM Proteins in African Swine Fever Virus Infection.
Muñoz-Moreno R; Cuesta-Geijo MÁ; Martínez-Romero C; Barrado-Gil L; Galindo I; García-Sastre A; Alonso C
PLoS One; 2016; 11(4):e0154366. PubMed ID: 27116236
[TBL] [Abstract][Full Text] [Related]
33. IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.
Yu J; Li M; Wilkins J; Ding S; Swartz TH; Esposito AM; Zheng YM; Freed EO; Liang C; Chen BK; Liu SL
Cell Rep; 2015 Oct; 13(1):145-156. PubMed ID: 26387945
[TBL] [Abstract][Full Text] [Related]
34. Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV.
Wilkins J; Zheng YM; Yu J; Liang C; Liu SL
PLoS One; 2016; 11(6):e0156739. PubMed ID: 27257969
[TBL] [Abstract][Full Text] [Related]
35. A membrane topology model for human interferon inducible transmembrane protein 1.
Weston S; Czieso S; White IJ; Smith SE; Kellam P; Marsh M
PLoS One; 2014; 9(8):e104341. PubMed ID: 25105503
[TBL] [Abstract][Full Text] [Related]
36. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity.
Tartour K; Appourchaux R; Gaillard J; Nguyen XN; Durand S; Turpin J; Beaumont E; Roch E; Berger G; Mahieux R; Brand D; Roingeard P; Cimarelli A
Retrovirology; 2014 Nov; 11():103. PubMed ID: 25422070
[TBL] [Abstract][Full Text] [Related]
37. IFITMs restrict the replication of multiple pathogenic viruses.
Perreira JM; Chin CR; Feeley EM; Brass AL
J Mol Biol; 2013 Dec; 425(24):4937-55. PubMed ID: 24076421
[TBL] [Abstract][Full Text] [Related]
38. The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus.
Warren CJ; Griffin LM; Little AS; Huang IC; Farzan M; Pyeon D
PLoS One; 2014; 9(5):e96579. PubMed ID: 24827144
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.
Waheed AA; Ablan SD; Roser JD; Sowder RC; Schaffner CP; Chertova E; Freed EO
Proc Natl Acad Sci U S A; 2007 May; 104(20):8467-71. PubMed ID: 17483482
[TBL] [Abstract][Full Text] [Related]
40. Biochemical evidence for conformational variants in the anti-viral and pro-metastatic protein IFITM1.
Nekulová M; Wyszkowska M; Friedlová N; Uhrík L; Zavadil Kokáš F; Hrabal V; Hernychová L; Vojtěšek B; Hupp TR; Szymański MR
Biol Chem; 2024 May; 405(5):311-324. PubMed ID: 38379409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
